Selective ophthalmic artery infusion chemotherapy for advanced intraocular retinoblastoma: CCHMC early experience

Samantha T. Michaels, Todd A. Abruzzo, James J. Augsburger, Zélia M. Correâ, Adam Lane, James I. Geller

Research output: Contribution to journalArticle

Abstract

Selective ophthalmic artery infusion chemotherapy (SOAIC) is increasingly used to treat retinoblastoma. We report the toxicities and outcome of 19 eyes in 17 patients with retinoblastoma receiving SOAIC treatment between 2008 and 2013. From the 87 treatments, mild local reactions were common. Myelosuppression was more common after triple-agent SOAIC (melphalan, carboplatin, and topotecan) than single-agent melphalan. Ocular salvage was achieved in 11 of 19 eyes and associated with triple-agent therapy. SOAIC is a effective therapy for some retinoblastoma with manageable toxicity; however, systemic toxicity increases with increasing therapeutic intensity of SOAIC.

Original languageEnglish (US)
Pages (from-to)65-69
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume38
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Keywords

  • Retinoblastoma
  • Selective ophthalmic artery infusion chemotherapy
  • Vitreal seeds

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Selective ophthalmic artery infusion chemotherapy for advanced intraocular retinoblastoma: CCHMC early experience'. Together they form a unique fingerprint.

  • Cite this